Health tech company SOPHiA GENETICS has announced the appointment of Kathy L. Hibbs to its Board of Directors and Audit Committee. Ms. Hibbs is Chief Legal and Regulatory Officer at consumer genetics and research company 23andMe, and will bring her expertise as an accomplished healthcare technology executive to help guide SOPHiA’s leaders.
"We are pleased to welcome Kathy to SOPHiA's Board of Directors," said SOPHiA GENETICS' CEO and Founder Jurgi Camblong. "The company will significantly benefit from Kathy's extensive experience in legal and regulatory affairs in the biotech industry specifically. She substantially contributed to the accessibility of genetic testing and usage of real-world evidence data, leading millions of people to more proactive health decisions, and is therefore totally aligned with our mission to democratize Data-Driven Medicine."
Ms. Hibbs is considered one of the most influential women in the Bay Area by both the San Francisco and Silicon Valley Business Journals, and one of the most influential General Counsels in the U.S. by Chambers. She has 15 years of experience as an executive officer and corporate secretary for biotechnology companies Genomic Health, Inc. and Monogram Biosciences, Inc..
"SOPHiA's position in the market and its rapid penetration in the US make it an exciting time to join the company," said Ms. Hibbs. "We share a common passion and a commitment to bring personalized medicine to the next chapter of its development; I find it truly inspiring, and I look forward to bringing my experience to the board."